Working… Menu

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00914771
Recruitment Status : Completed
First Posted : June 5, 2009
Last Update Posted : October 12, 2015
Information provided by (Responsible Party):
Novartis ( Novartis Vaccines )